NCT06179303 2026-04-16
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
Clinical Trials
15 trialsNCT04852887 2026-04-15
DEBRA
NRG Oncology
Phase 3 Recruiting
NCT05467891 2026-04-08
RaPhLRR
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06075953 2026-03-16
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT06218303 2026-03-12
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
University of Pittsburgh
Phase 1 Recruiting
NCT06507618 2026-02-24
POWER II
University of Virginia
Phase 3 Recruiting
NCT03624244 2026-02-17
BFR-ESS
Centre Leon Berard
Phase 2 Recruiting
NCT07019363 2026-01-21
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
Fudan University
Phase 3 Recruiting
NCT06364267 2025-11-18
BabyTears
Ente Ospedaliero Ospedali Galliera
Phase 2 Recruiting
NCT07190443 2025-09-29
AURA
Japanese Foundation for Cancer Research
Phase 3 Recruiting
NCT02476786 2025-07-28
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Washington University School of Medicine
Phase 2 Recruiting
NCT05472792 2025-05-23
CAMERAN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT04985266 2024-12-05
TRAK-ER
Royal Marsden NHS Foundation Trust
Phase 2 Recruiting
NCT05891093 2024-02-08
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Fudan University
Phase 3 Recruiting
NCT05890287 2023-06-06
A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase NA Recruiting